Persica Pharmaceuticals
Manufacturing · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Denne Hill Business Centre, Dennehill 7,...Phone Number
+44 1227910152Revenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Persica Pharmaceuticals
Persica Pharmaceuticals is a clinical stage biotechnology company focused on developing a groundbreaking non-opioid treatment for chronic Low Back Pain (cLBP) associated with Modic changes. Their primary product, PP353, is a patented intradiscal antibiotic injection designed to target the underlying cause of cLBP, offering a one-off treatment that minimizes systemic side effects. The company aims to address a significant unmet need in the healthcare market, with approximately 2 million patients in the US affected by this condition. By providing a novel therapeutic option, Persica Pharmaceuticals seeks to improve patient outcomes and reduce reliance on traditional analgesics.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Persica Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Persica Pharmaceuticals launches new products
Check out if Persica Pharmaceuticals is spiking on competitors!
Check if Persica Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if Persica Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Persica Pharmaceuticals
Funding: Get notified immidiatlly once Persica Pharmaceuticals has new funding data
Earning: See what the market has to say on Persica Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Persica Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Persica Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Persica Pharmaceuticals
Compare insights from companies similar to Persica Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Persica Pharmaceuticals
<$5M
1-10
Private
-
2013
N/A
Company Profile Activity
Activity Insights
Persica Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Persica Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Persica Pharmaceuticals.
Persica Pharmaceuticals Tech Stack
A closer look at the technologies used by Persica Pharmaceuticals
Most Recent Scoops
Person-Based
Events, Medical Research
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Lateral Move
Executive Move
Executive Moves, Lateral Move, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire, Board of Directors
Persica Pharmaceuticals News & Media
Persica Pharmaceuticals publishes new analyses of antibiotic exposure-response, reinforcing the scientific case for PP353 in vertebrogenic Lumbar Back Pain
London, UK, 04 September - Persica Pharmaceuticals Limited (“Persica”), a clinical-stage biotechnology company developing PP353, a targeted, non-opioid treatment for vertebrogenic Lumbar Back Pain (vLBP), today announces the publication of a study which brings together clinical and pharmacological evidence to address the question of why antibiotic studies in this patient population appear to report variable clinical outcomes.Persica Pharmaceuticals presents new analyses of microbiology assay sensitivity and intradiscal antibiotic exposure response in chronic Low Back Pain at ASPN 2026 Annual Conference
London, UK, 24 July 2026 - Persica Pharmaceuticals Limited (Persica), a clinical-stage biotechnology company developing PP353, a targeted, non-opioid treatment for vertebrogenic Lumbar Back Pain (vLBP), last week presented a new analyses of the methodological rigor of published disc microbiology studies, and antibiotic exposure-response to the American Society of Pain and Neuroscience (ASPN) 2026 Annual Conference, in Miami Beach, Florida.Persica Pharmaceuticals Appoints Dr Edward Littler as Executive Chairman and David Watson as Chief Executive Officer
New senior executives bring significant biopharma experience as Persica moves to next phase of its developmentPersica Pharmaceutical’s PP353 Phase 1b Data Selected for Oral Presentation at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting
ASIPP presentation follows publication of positive data from PP353 Phase 1b Modic Trial in The Lancet’s eClinicalMedicine
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Persica Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Persica Pharmaceuticals is a clinical stage biotechnology company focused on developing a groundbreaking non-opioid treatment for chronic Low Back Pain (cLBP) associated with Modic changes. Their primary product, PP353, is a patented intradiscal antibiotic injection designed to target the underlying cause of cLBP, offering a one-off treatment that... Read More
